Josiane Viana Cruz

Josiane Viana Cruz


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2020 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
RLRozires P. Leão
Rozires P. Leão
JCJosiane Viana Cruz
Josiane Viana Cruz
GCGlauber Costa
Glauber Costa
Jorddy N. CruzJorddy N. Cruz
Jorddy N. Cruz
EFELENILZE FIGUEIREDO FERREIRA
ELENILZE FIGUEIREDO FERREIRA
Cleydson Breno Rodrigues dos SantosCleydson Breno Rodrigues dos Santos
Cleydson Breno Rodrigues dos Santos
The cyclooxygenase-2 receptor is a therapeutic target for planning potential drugs with anti-inflammatory activity. The selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib was selected as a pivot molecule to perform virtual ligand-based screening from six commercial databases. We performed the search for similarly shaped Rapid Overlay of Chemical Structures (ROCS) and electrostatic (EON) compounds. After, we used pharmacokinetic and toxicological parameters to determine the best potential compounds, obtained through the softwares QikProp and Derek, respectively. Then, the compounds proceeded to the molecular anchorage study, which showed promising results of binding affinity with the hCOX-2 receptor: LMQC72 (∆G = −11.0 kcal/mol), LMQC36 (∆G = −10.6 kcal/mol), and LMQC50 (∆G = −10.2 kcal/mol). LMQC72 and LMQC36 showed higher binding affinity compared to rofecoxib (∆G = −10.4 kcal/mol). Finally, molecular dynamics (MD) simulations were used to evaluate the interaction of the compounds with the target hCOX-2 during 150 ns. In all MD simulation trajectories, the ligands remained interacting with the protein until the end of the simulation. The compounds were also complexing with hCOX-2 favorably. The compounds obtained the following affinity energy values: rofecoxib: ΔGbind = −45.31 kcal/mol; LMQC72: ΔGbind = −38.58 kcal/mol; LMQC36: ΔGbind = −36.10 kcal/mol; and LMQC50: ΔGbind = −39.40 kcal/mol. The selected LMQC72, LMQC50, and LMQC36 structures showed satisfactory pharmacokinetic results related to absorption and distribution. The toxicological predictions of these compounds did not display alerts for possible toxic groups and lower risk of cardiotoxicity compared to rofecoxib. Therefore, future in vitro and in vivo studies are needed to confirm the anti-inflammatory potential of the compounds selected here with bioinformatics approaches based on rofecoxib ligand.

19 January 2023 in Molecules
Verified
Journal Article
Open access
PDF file
LSLuciane Silva
Luciane Silva
EFELENILZE FERREIRA
ELENILZE FERREIRA
MSMaryam Rasool Satti
Maryam Rasool Satti
JRJosé Manuel Espejo Román
José Manuel Espejo Román
GCGlauber V. Costa
Glauber V. Costa
Cleydson Breno Rodrigues dos SantosCleydson Breno Rodrigues dos Santos
Cleydson Breno Rodrigues dos Santos
Acetylcholinesterase (AChE) enzymes play an essential role in the development of Alzheimer’s disease (AD). Its excessive activity causes several neuronal problems, particularly psychopathies and neuronal cell death. A bioactive pose on the hAChE B site of the human acetylcholinesterase (hAChE) enzyme employed in this investigation, which was obtained from the Protein Data Bank (PDB ID 4EY6), allowed for the prediction of the binding affinity and free binding energy between the protein and the ligand. Virtual screening was performed to obtain structures similar to Galantamine (GNT) with potential hAChE activity. The top 200 hit compounds were prioritized through the use of filters in ZincPharmer, with special features related to the pharmacophore. Critical analyses were carried out, such as hierarchical clustering analysis (HCA), ADME/Tox predictions, molecular docking, molecular simulation studies, synthetic accessibility (SA), lipophilicity, water solubility, and hot spots to confirm the stable binding of the two promising molecules (ZINC16951574-LMQC2, and ZINC08342556-LMQC5). The metabolism prediction, with metabolites M3-2, which is formed by Glutathionation reaction (Phase II), M1-2, and M2-2 formed from the reaction of S-oxidation and Aliphatic hydroxylation (Phase I), were both reactive but with no side effects. Theoretical synthetic routes and prediction of synthetic accessibility for the most promising compounds are also proposed. In conclusion, this study shows that in silico modeling can be used to create new drug candidate inhibitors for hAChE. The compounds ZINC16951574-LMQC2, and ZINC08342556-LMQC5 are particularly promising for oral administration because they have a favorable drug-likeness profile, excellent lipid solubility, high bioavailability, and adequate pharmacokinetics.

1 May 2022 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
JCJosiane Viana Cruz
Josiane Viana Cruz
JCJoaquín M. Campos
Joaquín M. Campos
Njogu M. KimaniNjogu M. Kimani
Njogu M. Kimani
SGSilvana Giuliatti
Silvana Giuliatti
Cleydson Breno Rodrigues dos SantosCleydson Breno Rodrigues dos Santos
Cleydson Breno Rodrigues dos Santos
This article aims at reviewing celecoxib as a potential inhibitor in the treatment of inflammatory diseases. The enzyme cyclooxygenase (COX) predominantly has two isoforms called cyclooxygenase 1 (COX-1) and cyclooxygenase 2 (COX-2). The former plays a constitutive role related to homeostatic effects in renal and platelets, while the latter is mainly responsible for the induction of inflammatory effects. Since COX-2 plays an important role in the pathogenesis of inflammatory diseases, it has been signaled as a target for the planning of anti-inflammatory intermediates. Many inhibitors developed and planned for COX-2 inhibition have presented side effects to humans, mainly in the gastrointestinal and/or cardiovascular tract. Therefore, it is necessary to design new potential COX-2 inhibitors, which are relatively safe and have no side effects. In this sense, celecoxib is the only potent, selective COX-2 inhibitor that is still commercially available (within the “coxib” family). Thus, celecoxib became a commercial prototype inhibitor for the development of anti-inflammatory agents for the COX-2 enzyme. This review provides inhibition highlights that should provide a structural basis for the design of promising new non-steroidal anti-inflammatory drugs (NSAIDs), which act as COX-2 inhibitors with lesser side effects on the human body.

18 February 2018 in Molecules
Verified
Journal Article
Open access
PDF file
JCJosiane Viana Cruz
Josiane Viana Cruz
MNMoysés F. A. Neto
Moysés F. A. Neto
LSLuciane Silva
Luciane Silva
Ryan da Silva RamosRyan da Silva Ramos
Ryan da Silva Ramos
JCJosivan Da Silva Costa
Josivan Da Silva Costa
Cleydson Breno Rodrigues dos SantosCleydson Breno Rodrigues dos Santos
Cleydson Breno Rodrigues dos Santos
The Protein Kinase Receptor type 2 (RIPK2) plays an important role in the pathogenesis of inflammatory diseases; it signals downstream of the NOD1 and NOD2 intracellular sensors and promotes a productive inflammatory response. However, excessive NOD2 signaling has been associated with various diseases, including sarcoidosis and inflammatory arthritis; the pharmacological inhibition of RIPK2 is an affinity strategy that demonstrates an increased expression of pro-inflammatory secretion activity. In this study, a pharmacophoric model based on the crystallographic pose of ponatinib, a potent RIPK2 inhibitor, and 30 other ones selected from the BindingDB repository database, was built. Compounds were selected based on the available ZINC compounds database and in silico predictions of their pharmacokinetic, toxicity and potential biological activity. Molecular docking was performed to identify the probable interactions of the compounds as well as their binding affinity with RIPK2. The compounds were analyzed to ponatinib and WEHI-345, which also used as a control. At least one of the compounds exhibited suitable pharmacokinetic properties, low toxicity and an interesting binding affinity and high fitness compared with the crystallographic pose of WEHI-345 in complex with RIPK2. This compound also possessed suitable synthetic accessibility, rendering it a potential and very promising RIPK2 inhibitor to be further investigated in regards to different diseases, particularly inflammatory ones.

7 August 2018 in Journal of Molecular Modeling
Verified
Journal Article
Closed access
PDF file
JCJosiane Viana Cruz
Josiane Viana Cruz
RSRodolfo B. Serafim
Rodolfo B. Serafim
GSGabriel M. da Silva
Gabriel M. da Silva
SGSilvana Giuliatti
Silvana Giuliatti
JRJoaquín M. C. Rosa
Joaquín M. C. Rosa
Cleydson Breno Rodrigues dos SantosCleydson Breno Rodrigues dos Santos
Cleydson Breno Rodrigues dos Santos

10 January 2021 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
JCJosiane Viana Cruz
Josiane Viana Cruz
SGSilvana Giuliatti
Silvana Giuliatti
LALevy B. Alves
Levy B. Alves
RSRai Campos Silva
Rai Campos Silva
EFElenilze F. B. Ferreira
Elenilze F. B. Ferreira
Cleydson Breno Rodrigues dos SantosCleydson Breno Rodrigues dos Santos
Cleydson Breno Rodrigues dos Santos
Cyclooxygenase 2 (COX-2) is a well-established target for the design of anti-inflammatory intermediates. Celecoxib was selected as a template molecule to perform ligand-based virtual screening, i.e. to search for structures with similarity in shape and electrostatic potential, with a gradual increase in accuracy through the combined fitting of several steps using eight commercial databases. The molecules ZINC408709 and ZINC2090319 reproduced values within the limits established in an initial study of absorption and distribution in the body. No alert was fired for possible toxic groups when these molecules were subjected to toxicity prediction. Molecular docking results with these compounds showed a higher binding affinity in comparison to rofecoxib for the COX-2 target. Additionally, ZINC408709 and ZINC2090319 were predicted to be potentially biologically active. In in silico prediction of endocrine disruption potential, it was established that the molecule ZINC2090319 binds strongly to the target related to cardiovascular risk in a desirable way as a non-steroidal antagonist and ZINC408709 binds strongly to the target that is associated with the treatment of inflammatory pathologies and similar to celecoxib. Metabolites generated from these compounds are less likely to have side effects. Simulations were used to evaluate the interaction of compounds with COX-1 and COX-2 during 200 ns. Despite the differences, ZINC408709 molecule showed better stability for COX-2 during molecular dynamics simulation. In the calculations of free energy MM/PBSA, the molecule ZINC408709 ΔGbind value has a higher affinity to celecoxib and rofecoxib COX-2. This demonstrates that the selected substances can be considered as promising COX-2 inhibitors. Communicated by Ramaswamy H. Sarma